Illumina Inc. is planning to move next-generation sequencing (NGS) into new markets by expanding its offerings in reproductive health and through the launch of leukocyte antigen typing product in mid-2014 for laboratories seeking next-generation sequencing. It will also continue to work in collaboration with the oncology community to develop test guidelines and infrastructure to build actionable cancer genomics solutions.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
121.4 USD | -3.10% |
|
+7.39% | -12.72% |
07-10 | Nvidia leads Nasdaq and S&P 500 to record highs | RE |
07-10 | Sector Update: Health Care Stocks Steady Premarket Wednesday | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.72% | 19.94B | |
+4.78% | 212B | |
+8.72% | 187B | |
+26.71% | 155B | |
+33.96% | 115B | |
+2.17% | 65.5B | |
+14.08% | 52.87B | |
-3.30% | 45.25B | |
-3.33% | 39.7B | |
+6.42% | 37.72B |
- Stock Market
- Equities
- ILMN Stock
- News Illumina, Inc.
- Illumina Inc. to Launch Leukocyte Antigen Typing Product in Mid-2014